On Invalid Date, Immunitybio (NASDAQ: IBRX) reported Q1 2024 earnings per share (EPS) of -$0.20, up 25.93% year over year. Total Immunitybio earnings for the quarter were -$134.11 million. In the same quarter last year, Immunitybio's earnings per share (EPS) was -$0.27.
As of Q2 2024, Immunitybio's earnings has grown year over year. Immunitybio's earnings in the past year totalled -$600.96 million.
What is IBRX's earnings date?
Immunitybio's earnings date is Invalid Date. Add IBRX to your watchlist to be reminded of IBRX's next earnings announcement.
What was IBRX's revenue last quarter?
On Invalid Date, Immunitybio (NASDAQ: IBRX) reported Q1 2024 revenue of $40.00 thousand up 88.89% year over year. In the same quarter last year, Immunitybio's revenue was $360.00 thousand.
What was IBRX's revenue growth in the past year?
As of Q2 2024, Immunitybio's revenue has grown -48.46% year over year. This is 131.42 percentage points lower than the US Biotechnology industry revenue growth rate of 82.96%. Immunitybio's revenue in the past year totalled $302.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.